Want to join the conversation?
$EMN's sales for 3Q15 increased by $34MM from last year, primarily due to sales volume from acquired businesses, mostly offset by lower selling prices, particularly in Specialty Fluids & Intermediates and Additives & Functional Products segments on lower raw material and energy costs, and unfavorable shift in FX rates.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.